Susquehanna International Group, LLP Adamis Pharmaceuticals Corp Call Options Transaction History

Susquehanna International Group, LLP

16 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2023 May 16, 2023	SELL	$0.1 - $0.3 $24,580 - $73,740	-245,800 Reduced 86.12%	39,600 $4,000
Q4 2022 Feb 14, 2023	SELL	$0.14 - $0.22 $896 - $1,408	-6,400 Reduced 2.19%	285,400 $48,000
Q3 2022 Nov 14, 2022	SELL	$0.24 - $0.54 $12,240 - $27,540	-51,000 Reduced 14.88%	291,800 $58,000
Q2 2022 Aug 15, 2022	SELL	$0.34 - $0.57 $1,156 - $1,937	-3,400 Reduced 0.98%	342,800 $171,000
Q1 2022 May 16, 2022	SELL	$0.55 - $0.73 $4,510 - $5,986	-8,200 Reduced 2.31%	346,200 $197,000
Q4 2021 Feb 14, 2022	SELL	$0.57 - $1.23 $105,848 - $228,411	-185,700 Reduced 34.38%	354,400 $216,000
Q3 2021 Nov 15, 2021	BUY	$0.92 - $1.18 $265,420 - $340,430	288,500 Added 114.67%	540,100 $524,000
Q2 2021 Aug 11, 2021	SELL	$0.66 - $1.23 $137,346 - $255,963	-208,100 Reduced 45.27%	251,600 $277,000
Q1 2021 May 17, 2021	BUY	$0.54 - $1.79 $228,204 - $756,454	422,600 Added 1139.08%	459,700 $432,000
Q3 2020 Nov 16, 2020	BUY	$0.52 - $1.45 $4,992 - $13,920	9,600 Added 34.91%	37,100 $29,000
Q2 2019 Aug 14, 2019	SELL	$1.26 - $2.23 $33,012 - $58,426	-26,200 Reduced 48.79%	27,500 $36,000
Q1 2019 May 15, 2019	SELL	$2.02 - $3.22 $14,746 - $23,506	-7,300 Reduced 11.97%	53,700 $113,000
Q2 2018 Aug 14, 2018	SELL	$3.2 - $4.7 $304,320 - $446,970	-95,100 Reduced 60.92%	61,000 $195,000
Q1 2018 May 15, 2018	BUY	$2.55 - $4.85 $194,055 - $369,085	76,100 Added 95.13%	156,100 $546,000
Q4 2017 Feb 14, 2018	BUY	$3.5 - $5.65 $233,800 - $377,420	66,800 Added 506.06%	80,000 $352,000
Q3 2017 Nov 14, 2017	BUY	$4.5 - $5.65 $59,400 - $74,580	13,200	13,200 $69,000

Ticker ADMP
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 149,983,008
Market Cap $73.5M
Description
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States. The company's product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emerg...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.